Moderate

Psoriatic arthritis (PsA) — peripheral, axial, enthesitis & dactylitis

Psoriatic arthritis · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Seronegative inflammatory arthritis associated with psoriasis (skin psoriasis precedes arthritis in ~70%, but ~15% arthritis-first). Heterogeneous domains: peripheral arthritis (asymmetric oligoarthritis or symmetric polyarthritis, DIP involvement), axial disease (sacroiliitis/spondylitis), enthesitis (Achilles, plantar fascia), dactylitis ('sausage digit'), nail disease (pitting, onycholysis). Part of the spondyloarthritis family; HLA-B27 associated with axial disease. Can be erosive/mutilating. Managed by domain-based treatment escalation (GRAPPA/EULAR).

Red flags

  • Painful red eye + photophobia — anterior uveitis (urgent ophthalmology)
  • Arthritis mutilans — rapidly destructive, telescoping digits (aggressive early biologic)
  • New/worsening GI symptoms on IL-17 inhibitor — may unmask/flare inflammatory bowel disease
  • Hot single joint with fever — exclude septic arthritis (aspirate)
  • Inflammatory back pain with neurology — advanced axial disease/fracture through ankylosed spine

Assessment

Differential diagnosis

  • Rheumatoid arthritis (symmetric, RF/anti-CCP positive, spares DIP, no enthesitis/dactylitis)
  • Ankylosing spondylitis / axial SpA (axial without psoriasis/nail disease)
  • Reactive arthritis (post-infective, similar SpA features)
  • Gout (first MTP, tophi, crystals — can coexist; psoriasis raises urate)
  • Osteoarthritis of DIP (Heberden nodes, no inflammation/nail pits)

Investigations

  • RF and anti-CCP (usually negative — supports seronegative SpA)
  • ESR/CRP (may be normal despite active disease)
  • X-rays: 'pencil-in-cup' deformity, DIP erosions with new bone, fluffy periostitis, asymmetric sacroiliitis
  • HLA-B27 (axial/enthesitis phenotype)
  • Ultrasound/MRI for enthesitis, synovitis, early sacroiliitis
  • Skin/nail exam (hidden psoriasis: scalp, umbilicus, natal cleft, nails); uric acid to exclude gout

Management

  • Confirm diagnosis (CASPAR criteria: inflammatory articular disease + psoriasis/history/nail changes + negative RF + dactylitis + juxta-articular new bone)
  • Identify active domains (peripheral, axial, enthesitis, dactylitis, skin, nails) — treatment is domain-driven
  • Mild peripheral/monoarthritis: NSAIDs +/- intra-articular steroid; start csDMARD early if persistent/polyarticular
  • Peripheral polyarthritis: csDMARD (methotrexate first; leflunomide/sulfasalazine alternatives) — also treats skin
  • Inadequate response or poor prognosis (erosions, high activity): escalate to biologic — TNF inhibitor, IL-17 inhibitor, or IL-23/IL-12-23 inhibitor; or JAK inhibitor; or PDE4 inhibitor (apremilast) for milder disease
  • Axial-predominant disease: csDMARDs ineffective for spine — go to NSAIDs then biologic (TNFi or IL-17i; avoid IL-23i for pure axial)
  • Predominant enthesitis/dactylitis: TNFi, IL-17i, IL-23i, JAKi or apremilast (csDMARDs less effective for enthesitis)
  • Co-manage skin psoriasis with dermatology; screen and manage cardiometabolic comorbidity (obesity, metabolic syndrome, uveitis, IBD)

Drugs & doses

NSAID e.g. naproxen 500 mg ORALLY twice daily or etoricoxib 60-90 mg daily with PPI cover (first-line symptom control)
Intra-articular triamcinolone (large joint 40 mg, small joint 10 mg) or into dactylitic digit/enthesis [verify local dose]
Methotrexate 15 mg ORALLY weekly titrate to 25 mg/week + folic acid 5 mg weekly (peripheral arthritis + skin) [verify local dose]
Sulfasalazine 1 g twice daily or leflunomide 20 mg daily (alternative csDMARDs for peripheral disease)
Apremilast (PDE4 inhibitor) 30 mg ORALLY twice daily after titration (milder disease, enthesitis; no lab monitoring) [verify local]
TNF inhibitor e.g. adalimumab 40 mg SC every 2 weeks or etanercept 50 mg SC weekly (screen TB/HBV first) [verify local]
IL-17 inhibitor e.g. secukinumab 150-300 mg SC or ixekizumab (good for skin/axial; caution in IBD) [verify local]
IL-23/IL-12-23 inhibitor e.g. guselkumab or ustekinumab SC (strong for skin; avoid as monotherapy for active axial disease) [verify local]
JAK inhibitor e.g. tofacitinib or upadacitinib ORALLY (weigh MACE/VTE/malignancy risk) [verify local]

Disposition

Outpatient rheumatology (+ dermatology co-management). ED/primary care: start NSAID/intra-articular steroid, refer for DMARD initiation. Urgent same-day if suspected uveitis or septic joint.

Complications & pitfalls

  • Erosive joint damage, arthritis mutilans, functional disability
  • Uveitis, inflammatory bowel disease association
  • Increased cardiovascular and metabolic syndrome risk
  • Axial ankylosis and reduced spinal mobility
  • Psychological burden of combined skin + joint disease

Exam pearls

  • GRAPPA/EULAR 2021-2023: treatment is domain-based — csDMARDs work for peripheral arthritis but NOT for axial disease or enthesitis, where biologics are needed.
  • Choose biologic by comorbidity: IL-17i excellent for skin but avoid in active IBD; IL-23i strong for skin not for pure axial disease.
  • Always examine nails and hidden sites (scalp, natal cleft, umbilicus) — psoriasis may be subtle and is the diagnostic clue.
  • Dactylitis and enthesitis are hallmark SpA features distinguishing PsA from RA.
  • Screen for and treat cardiometabolic risk and depression — major comorbidities.
  • JAK inhibitor caution mirrors RA (age >65, smoker, prior MACE/VTE/malignancy).

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.